Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis

Página do item simplificado
dc.contributor.authorNunes, Vânia dos Santos [UNESP]
dc.contributor.authorEl Dib, Regina [UNESP]
dc.contributor.authorBoguszewski, Cesar Luiz
dc.contributor.authorNogueira, Célia Regina [UNESP]
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversidade Federal do Paraná (UFPR)
dc.date.accessioned2014-05-20T13:33:23Z
dc.date.available2014-05-20T13:33:23Z
dc.date.issued2011-09-01
dc.description.abstractCabergoline and bromocriptine are the most used drugs in the treatment of hyperprolactinemia, they are able to normalize the prolactin levels, restore gonadal function and promote tumor reduction in the majority of patients. We undertake a systematic review and meta-analysis of randomized controlled trials to compare cabergoline versus bromocriptine in the treatment of patients with idiopathic hyperprolactinemia and prolactinomas. The data sources were: Embase, Pubmed, Lilacs and Cochrane Central. The outcome measures were: normalization of prolactin secretion, restoration of gonadal function, reduction of tumoral volume, quality of life and adverse drug effects. Were identified 418 references and after screening by title and abstract, we obtained complete copies of 34 articles potentially eligible for inclusion in the review. From this total, 19 were selected to be included, but fifteen of them were excluded due to the following reasons: one randomized study compared cabergoline versus placebo and other randomized study compared different doses of cabergoline; five references were cases series; four were only controlled studies; three were retrospectives series and; one was a cohort study. Therefore, four publications were included in the review and in the final analysis. The meta-analysis of normalization of serum prolactin levels and menstruation with return of ovulatory cycle showed a significant difference in favor of cabergoline group (RR 0.67 [CI 95% 0.57, 0.80]) e (RR 0.74 [CI 95% 0.67, 0.83]), respectively. The number of adverse effects was significantly higher in the bromocriptine number than in cabergoline group (RR 1.43 [CI 95% 1.03, 1.98]). The meta-analysis showed new evidence favoring the use of cabergoline in comparison with bromocriptine for the treatment of prolactinomas and idiopathic hyperprolactinemia.en
dc.description.affiliationFac Med Botucatu, Dept Clin Med, BR-18618970 Botucatu, SP, Brazil
dc.description.affiliationState Univ Unesp, Dept Internal Med, Botucatu Med Sch, São Paulo, Brazil
dc.description.affiliationUniversidade Federal do Paraná (UFPR), Dept Internal Med, Endocrine Div SEMPR, BR-80060000 Curitiba, Parana, Brazil
dc.description.affiliationUnespState Univ Unesp, Dept Internal Med, Botucatu Med Sch, São Paulo, Brazil
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipIdCNPq: 576445/08-8
dc.format.extent259-265
dc.identifierhttp://dx.doi.org/10.1007/s11102-010-0290-z
dc.identifier.citationPituitary. New York: Springer, v. 14, n. 3, p. 259-265, 2011.
dc.identifier.doi10.1007/s11102-010-0290-z
dc.identifier.issn1386-341X
dc.identifier.urihttp://hdl.handle.net/11449/11433
dc.identifier.wosWOS:000293288900009
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofPituitary
dc.relation.ispartofjcr2.730
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.subjectHyperprolactinemiaen
dc.subjectProlactinomaen
dc.subjectSystematic reviewen
dc.subjectMeta-analysisen
dc.subjectDopaminergic agonistsen
dc.titleCabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysisen
dc.typeArtigo
dcterms.licensehttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dcterms.rightsHolderSpringer
unesp.author.lattes7607038776901890[4]
unesp.author.orcid0000-0002-7354-9518[4]
unesp.author.orcid0000-0001-9316-4167[1]
unesp.author.orcid0000-0002-4081-803X[2]
unesp.author.orcid0000-0002-4014-0660[4]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt

Arquivos

Licença do Pacote
Agora exibindo 1 - 2 de 2
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:

Coleções

Artigos - Clínica Médica - FMB